MedTrace Logo

Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose

NCT00972725 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2018-08-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and reactogenicity of one booster dose of a HIV candidate vaccine after administration of one oral dose of chloroquine.

Conditions

  • AIDS

Interventions

BIOLOGICAL

GSK Biologicals' HIV vaccine (732461)

1 dose intramuscular injection

DRUG

Chloroquine

One dose of 300 mg

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
52 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-01
Primary Completion
2010-10-04
Completion
2010-10-04

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00972725 on ClinicalTrials.gov